August 23, 2021
Astellas Pharma and partner FibroGen said on August 20 that their HIF-PH inhibitor Evrenzo (roxadustat) has received European regulatory approval for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD). Evrenzo is being jointly developed...read more